← Leaderboards
Georg T Wondrak
University Of Arizona
$5,087,049
Attributed
$5,265,810
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2007–23$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,926,413 · 10
By mechanism
P01$3,724,649 · 3
R01$2,983,045 · 2
R21$766,610 · 2
R03$452,109 · 3
Top collaborators
- Clara Curiel-Lewandrowski2 shared
- Donna D Zhang2 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Clara Curiel-Lewandrowski$4,151,872
- David S Alberts$22,074,619
- George Timothy Bowden$6,009,884
- Steven P Stratton$2,491,979
- Donna D Zhang$16,636,334
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMolecularMolecular TargetBaseCellsSkinIncidenceGeneticPrototypeTumorCell Culture TechniquesMelanomaResistanceSkin CancerSignal TransductionUnited StatesMouse ModelApoptosisPublic HealthCytotoxicCancer CellProteomicsPre-ClinicalPathway Interactions
Grant awards (28)
Targeted Prevention for Non-Melanoma Skin Cancer$1,301,234
P01 · FY2023 · CA
Repurposing Clinical ACT Antimalarials for Experimental Melanoma Intervention$328,815
R01 · FY2023 · CA · contact PI
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention$197,660
P01 · FY2023 · CA · contact PI
Targeted Prevention for Non-Melanoma Skin Cancer$1,359,369
P01 · FY2022 · CA
Repurposing Clinical ACT Antimalarials for Experimental Melanoma Intervention$329,948
R01 · FY2022 · CA · contact PI
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention$194,344
P01 · FY2022 · CA · contact PI
Repurposing Clinical ACT Antimalarials for Experimental Melanoma Intervention$337,751
R01 · FY2021 · CA · contact PI
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention$197,988
P01 · FY2021 · CA · contact PI
Repurposing Clinical ACT Antimalarials for Experimental Melanoma Intervention$338,743
R01 · FY2020 · CA · contact PI
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention$237,027
P01 · FY2020 · CA · contact PI
Exploring the role of HOCI in skin photodamage, immunosuppression, and carcinogenesis$185,106
R21 · FY2020 · ES · contact PI
Repurposing Clinical ACT Antimalarials for Experimental Melanoma Intervention$339,661
R01 · FY2019 · CA · contact PI
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention$237,027
P01 · FY2019 · CA · contact PI
Exploring the role of HOCI in skin photodamage, immunosuppression, and carcinogenesis$223,982
R21 · FY2019 · ES · contact PI
Zinc dysregulation as a druggable target in human skin photocarcinogenesis$73,432
R03 · FY2019 · CA · contact PI
Bixin-based dietary skin photoprotection and suppression of photocarcinogenesis$76,750
R03 · FY2018 · CA · contact PI
Zinc dysregulation as a druggable target in human skin photocarcinogenesis$73,677
R03 · FY2018 · CA · contact PI
Bixin-based dietary skin photoprotection and suppression of photocarcinogenesis$76,750
R03 · FY2017 · CA · contact PI
Targeting colorectal carcinogenesis using a cinnamon-derived food factor$159,814
R21 · FY2014 · CA · contact PI
Targeting colorectal carcinogenesis using a cinnamon-derived food factor$197,708
R21 · FY2013 · CA · contact PI
Testing feasibility of artemisinin-based synthetic-lethal suppression of skin pho$75,750
R03 · FY2013 · CA · contact PI
Testing feasibility of artemisinin-based synthetic-lethal suppression of skin pho$75,750
R03 · FY2012 · CA · contact PI
Targeting Glycolytic Control of Melanoma Cell Survival$221,058
R01 · FY2011 · CA · contact PI
Targeting Glycolytic Control of Melanoma Cell Survival$227,895
R01 · FY2010 · CA · contact PI
Targeting Glycolytic Control of Melanoma Cell Survival$227,895
R01 · FY2009 · CA · contact PI
Targeting Glycolytic Control of Melanoma Cell Survival$175,489
R01 · FY2009 · CA · contact PI
Targeting Glycolytic Control of Melanoma Cell Survival$227,895
R01 · FY2008 · CA · contact PI
Targeting Glycolytic Control of Melanoma Cell Survival$227,895
R01 · FY2007 · CA · contact PI